Stephanie Monaghan O'Brien is a corporate insider at Apellis Pharmaceuticals, Inc. (APLS). O'Brien has reported 4 insider filings with the SEC since 2026. The most recent filing was in May 2026.
Every role Stephanie Monaghan O'Brien has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
Apellis Pharmaceuticals, Inc. (APLS)3 filingsUpdated Aug 30, 2026
Stephanie Monaghan O'Brien files SEC Form 4 reports at Apellis Pharmaceuticals, Inc. (APLS). 3 SEC Form 4 filings on record, most recently on 14 May 2026.
Every recent SEC Form 4 transaction Stephanie Monaghan O'Brien has reported, most recent first.
InsiderAlpha's records for Stephanie Monaghan O'Brien go back to 2026: 3 primary Form 4 filings, an average of 3.0 per year. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Insiders who reported open-market trades in the last 12 months at the companies Stephanie Monaghan O'Brien files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Stephanie Monaghan O'Brien is a corporate insider of Apellis Pharmaceuticals, Inc. (APLS). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
The most recent primary Form 4 on record is dated 14 May 2026, one of 3 filings going back to 2026.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
$APLS Apellis Pharmaceuticals, Inc.8.0K shares @ --